Ішек суы мен электролит теңсіздігін тудыратын ісік

A tumor that often causes a syndrome of diarrhea and electrolyte imbalance

A VIPoma or vipoma (/v//ɪ/'/p//oʊ//m//ə/) is a rare endocrine tumor that overproduces vasoactive intestinal peptide (thus VIP + oma). The incidence is about 1 per 10,000,000 per year. VIPomas usually (about 90%) originate from the non β islet cells of the pancreas. They are sometimes associated with multiple endocrine neoplasia type 1. Roughly 50–75% of VIPomas are malignant, but even when they are benign, they are problematic because they tend to cause a specific syndrome: the massive amounts of VIP cause a syndrome of profound and chronic watery diarrhea and resultant dehydration, hypokalemia, achlorhydria, acidosis, flushing and hypotension (from vasodilation), hypercalcemia, and hyperglycemia. This syndrome is called Verner–Morrison syndrome (VMS), WDHA syndrome (from watery diarrhea–hypokalemia–achlorhydria), or pancreatic cholera syndrome (PCS). The eponym reflects the physicians who first described the syndrome.

The major clinical features are prolonged watery diarrhea (fasting stool volume > 750 to 1000 mL/day) and symptoms of hypokalemia and dehydration. Half of the patients have relatively constant diarrhea while the rest have alternating periods of severe and moderate diarrhea. One third have diarrhea < 1yr before diagnosis, but in 25%, diarrhea is present for 5 yr or more before diagnosis. Lethargy, muscle weakness, nausea, vomiting and crampy abdominal pain are frequent symptoms. Hypokalemia and impaired glucose tolerance occur in < 50% of patients. Achlorhydria is also a feature. During attacks of diarrhea, flushing similar to the carcinoid syndrome occur rarely.

The first goal of treatment is to correct dehydration. Fluids are often given through a vein (intravenous fluids) to replace fluids lost in diarrhea. The next goal is to slow the diarrhea. Some medications can help control diarrhea. Octreotide, which is a human made form of the natural hormone somatostatin, blocks the action of VIP. The best chance for a cure is surgery to remove the tumor. If the tumor has not spread to other organs, surgery can often cure the condition. For metastatic disease, peptide receptor radionuclide therapy (PRRT) can be highly effective. This treatment involves attaching a radionuclide (Lutetium 177 or Yttrium 90) to a somatostatin analogue (octreotate or octreotide). This is a novel way to deliver high doses of beta radiation to kill tumours. Some people seem to respond to a combination chemo called capecitabine and temozolomide but there is no report that it totally cured people of VIPoma.

Surgery can usually cure VIPomas. However, in one third to one half of patients, the tumor has spread by the time of diagnosis and cannot be cured.